Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

This study explored a new treatment approach using 20% TCA application with topical bimatoprost solution for managing alopecia areata of the eyebrows in cases where traditional treatments failed, offering a potential additional option for difficult cases.

This study found that introducing rat ornithine transcarbamylase gene into spf-ash mice improved liver and intestinal enzyme activity and normalized some metabolic indicators.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Temporal triangular alopecia is a non-scarring hair loss seen in some Asian children.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

In this study, researchers at Jawaharlal Nehru Medical College are comparing the effectiveness and side effects of Adapalene gel (0.1%) and Tazarotene gel (0.05%) in acne treatment among patients aged 12-35, with assessments every 4, 8, and 12 weeks. Results are not reported yet.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study found that a combination therapy of subcision, micro-needling, and TCA CROSS led to significant improvement in atrophic acne scars, with many patients showing improved scar grades over the treatment period.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

The researchers reported that in a mouse model of alopecia areata, tofacitinib treatment influenced disease progression by modulating CD8⁺ T cell infiltration through the linoleic acid metabolism and magnesium ion pathway, offering insights into potential treatment approaches.

This article presents a toolkit created by the FTA to help transit agencies manage employees' use of medications that could impact public safety, but it reports no new results.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

In this study, introducing the rat OTC gene into spf-ash mice led to increased OTC activity and normalized hair growth and biochemical markers like urinary orotic acid and serum citrulline, partially correcting the symptoms of OTC deficiency.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This article discusses the trichoscopic diagnosis of temporal triangular alopecia, but reports no new clinical results.